New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer

doi:10.5320/wjr.v6.i2.57

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10016)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

507

WORD

274

HTML

4384

Figures (1-2)

146

Tables (1-3)

167

Sum=5478

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

681

Download

1551

Sum=2232

Publishing Process of This Article

Item

Count

Browse

907

Download

1399

Sum=2306

Jul 28, 2016 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Respirology

ISSN

2218-6255

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Frontier

World J Respirol. Jul 28, 2016; 6(2): 57-62
Published online Jul 28, 2016. doi: 10.5320/wjr.v6.i2.57

Table 1 Results from studies with tyrosine kinase inhibitor’s in 1^st line treatment of non-small cell lung cancer

Study and ref.	n	Treatment	RR (%)	P	PFS (mo)	HR	OS (mo)	HR
Study and ref.	n	Treatment	RR (%)	P	PFS (mo)	P	OS (mo)	P
IPASS[9]	437	Gefitinib/	71.2/47.3	0.01	9.5/5.3	0.48	21.6/21.9	0.99
IPASS[9]	437	Carboplatin + Paclitaxel	71.2/47.3	0.01	9.5/5.3	(< 0.001)	21.6/21.9	0.99
WJTOG[10]	177	Gefitinib/	62.1/32.2	0.01	9.2/6.3	0.49	30.9/NA	1.64
WJTOG[10]	177	Cisplatin + Docetaxel	62.1/32.2	0.01	9.2/6.3	-0.001	30.9/NA	1.64
NEJ[11]	230	Gefitinib/	73.7/30.7	0.01	10.8/5.4	0.3	30.5/23.6	NA
NEJ[11]	230	Carboplatin + Paclitaxel	73.7/30.7	0.01	10.8/5.4	-0.001	30.5/23.6	NA
OPTIMAL[12]	154	Erlotinib/	83/36	0.01	13.1/4.6	0.16	22.6/28.8	1.06
		Carboplatin + Gemcitabin				-0.001

EURTAC[13]	173	Erlotinib/	58/15	0.01	9.7/5.2	0.37	19.3/19.5	1.04
EURTAC[13]	173	Platin doublet	58/15	0.01	9.7/5.2	-0.001	19.3/19.5	1.04
LUX-LUNG3[14]	345	Afatinib/	56/23	0.01	11.1/6.9	0.58	NA	1.12
LUX-LUNG3[14]	345	Cisplatin + pemetrexed	56/23	0.01	11.1/6.9	-0.001	NA	1.12

NA: Not available; RR: Response rate; PFS: Progression free survival; HR: Hazard ratio; OS: Overall survival.

Citation: Macedo JE. New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer. World J Respirol 2016; 6(2): 57-62
URL: https://www.wjgnet.com/2218-6255/full/v6/i2/57.htm
DOI: https://dx.doi.org/10.5320/wjr.v6.i2.57